Serina Therapeutics, Inc. (SER)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

2Y 5Y 10Y All
Quarterly Annual TTM

Revenue TTM

0 1.5M 3M 4.5M Q1 '20: 1.4M Q2 '20: 1.1M Q3 '20: 752K Q4 '20: 361K Q1 '21: 328K Q2 '21: 320K Q3 '21: 275K Q4 '21: 144K Q1 '22: 93K Q2 '22: 68K Q3 '22: 53K Q4 '22: 34K Q1 '23: 59K Q2 '23: 54K Q3 '23: 74K Q4 '23: 3.2M Q1 '24: 3.1M Q2 '24: 3.2M Q3 '24: 3.2M Q4 '25: 130K Q2 '20 Q1 '21 Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '25

Gross Profit TTM

0 600K 1.2M 1.8M Q1 '19: 1.2M Q2 '19: 1.2M Q3 '19: 1.1M Q4 '19: 1.5M Q1 '20: 1.2M Q2 '20: 962K Q3 '20: 652K Q4 '20: 335K Q1 '21: 300K Q2 '21: 282K Q3 '21: 252K Q4 '21: 125K Q1 '22: 76K Q2 '22: 58K Q3 '22: 40K Q4 '22: 21K Q1 '23: 26K Q2 '23: 24K Q3 '23: 54K Q4 '23: 102K Q2 '19 Q1 '20 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23

Operating Income TTM

-27M -18M -9M 0 9M 18M 27M Q1 '21: -9.3M Q2 '21: -9.1M Q3 '21: -8.4M Q4 '21: -7.9M Q1 '22: -7.8M Q2 '22: -7.2M Q3 '22: -7.1M Q4 '22: -7M Q1 '23: -5.9M Q2 '23: -5.2M Q3 '23: -5.2M Q4 '23: -3.1M Q1 '24: -4.5M Q2 '24: -7.4M Q3 '24: -11.3M Q4 '24: -17M Q1 '25: -20.6M Q2 '25: -22.3M Q3 '25: -23.4M Q4 '25: -24M Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25 Q4 '25

Net Income TTM

-24M -16M -8M 0 8M 16M 24M Q3 '21: -9M Q4 '21: -8.7M Q1 '22: -9.3M Q2 '22: -9.4M Q3 '22: -9.9M Q4 '22: -10.5M Q1 '23: -6.1M Q2 '23: -2.7M Q3 '23: 1.5M Q4 '23: 5.3M Q1 '24: -11.4M Q2 '24: -7M Q3 '24: -7.3M Q4 '24: -11.1M Q1 '25: -939K Q2 '25: -12.6M Q3 '25: -18.6M Q4 '25: -19.2M Q1 '26: -21.3M Q2 '26: -21.2M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 150K 300K 450K Q1 '19: 318K Q2 '19: 292K Q3 '19: 345K Q4 '19: 244K Q1 '20: 182K Q2 '20: 132K Q3 '20: 100K Q4 '20: 26K Q1 '21: 28K Q2 '21: 38K Q3 '21: 23K Q4 '21: 19K Q1 '22: 17K Q2 '22: 10K Q3 '22: 13K Q4 '22: 13K Q1 '23: 13K Q2 '23: 12K Q3 '23: 40K Q4 '23: 40K Q2 '19 Q1 '20 Q4 '20 Q3 '21 Q2 '22 Q1 '23 Q4 '23

Operating Cash Flow TTM

-24M -16M -8M 0 8M 16M 24M Q3 '21: -7.8M Q4 '21: -7.9M Q1 '22: -6.9M Q2 '22: -6.9M Q3 '22: -6.3M Q4 '22: -5.9M Q1 '23: -5M Q2 '23: -4.1M Q3 '23: -3.9M Q4 '23: -2.5M Q1 '24: -3.3M Q2 '24: -10.5M Q3 '24: -12.4M Q4 '24: -17.1M Q1 '25: -19.9M Q2 '25: -15.6M Q3 '25: -16.5M Q4 '25: -18M Q1 '26: -18.2M Q2 '26: -21.1M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-24M -16M -8M 0 8M 16M 24M Q4 '18: -8M Q1 '19: -8.6M Q2 '19: -9.3M Q3 '19: -10.1M Q4 '19: -10.8M Q1 '20: -10.2M Q2 '20: -9.6M Q3 '20: -8.9M Q4 '20: -7.8M Q4 '24: -17.2M Q1 '25: -19.9M Q2 '25: -15.7M Q3 '25: -16.6M Q4 '25: -18M Q1 '26: -18.3M Q2 '26: -21.2M Q1 '19 Q3 '19 Q1 '20 Q3 '20 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 15M 30M 45M Q1 '21: 37.7M Q2 '21: 37.9K Q3 '21: 37.9M Q1 '22: 37.9M Q2 '22: 37.9K Q3 '22: 37.9K Q1 '23: 8.6M Q2 '23: 7.4K Q3 '23: 7.6M Q1 '24: 2.8M Q2 '24: 10.2M Q3 '24: 10.8M Q1 '25: 9.8M Q2 '25: 10M Q3 '25: 10.3M Q1 '26: 12M Q2 '26: 16.4M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-6.00 -4.00 -2.00 0.00 2.00 4.00 6.00 Q4 '18: -0.22 Q1 '19: -0.30 Q2 '19: -0.32 Q3 '19: -0.35 Q4 '19: -0.34 Q1 '20: -0.33 Q2 '20: -0.32 Q3 '20: -0.30 Q4 '20: -0.29 Q1 '21: -0.27 Q2 '24: -4.48 Q3 '24: -4.58 Q4 '25: -1.91 Q1 '26: -2.00 Q2 '26: -1.89 Q4 '18 Q2 '19 Q4 '19 Q2 '20 Q4 '20 Q2 '24 Q4 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.